CJC-1295 No DAC — 2 mg

CJC-1295 No DAC is commonly identified in research catalogs as modified GRF(1–29), a synthetic analogue of the active beginning of growth-hormone-releasing hormone. Umbrella Labs describes four amino-acid substitutions intended to reduce enzymatic breakdown. Its proposed action is stimulation of the GHRH receptor and subsequent release of growth hormone from the pituitary, rather than direct replacement of growth hormone. The seller presents it as more resistant to degradation than sermorelin while still relatively short acting, making duration of endocrine stimulation a central research interest.

The broader modified-GRF development literature explores how sequence changes and albumin attachment affect stability, receptor activity and GH release. Jetté and colleagues found that albumin-linked GRF analogues retained biological activity in pituitary-cell assays and experimental rats. Human work by Teichman and colleagues subsequently reported prolonged GH and IGF-1 increases with the long-acting CJC-1295 molecule. Those particular findings concern the DAC-containing compound. For the no-DAC product, the seller’s defining claims are enzyme resistance and GHRH-pathway activity without the albumin-binding complex; the two forms therefore remain separate research materials rather than interchangeable names.